Real-time regulatory updates from DEA, DOJ, FDA, CMS, and all 50 state medical boards — curated and analyzed by AI, reviewed by compliance experts. Built to help you stay ahead of healthcare regulation changes.
All 50 States + DC
350+ Regulatory Topics
Regulatory Intelligence Feed
0 articles published
Guides & Templates
In-Depth Compliance Resources
Comprehensive guides, checklists, and templates to help you navigate healthcare compliance — from CPOM structuring to GFE requirements and medical director agreements.
Our AI-powered intelligence engine monitors DEA, DOJ, FDA, CMS, and all 50 state medical boards so you never miss a compliance update that affects your business.
A chiropractor from Jacksonville, Illinois, Sean Rondeau, has been sentenced to federal prison and supervised release for defrauding health insurance companies. The convictions include healthcare fraud, mail fraud, and wire fraud, totaling over a quarter million dollars in losses.
The Drug Enforcement Administration (DEA) has issued a final rule adopting provisions from the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018 (SUPPORT Act) and the Restoring Hope for Mental Health and Well-Being Act of 2022. This rule eliminates the DATA-waiver program for prescribing buprenorphine for opioid use disorder (OUD) and implements a new one-time training requirement for all controlled substance prescribers. It also codifies provisions allowing pharmacies to deliver certain controlled substances to a practitioner's registered location for maintenance or detoxification treatment.
A former Newark Deputy Mayor and Director of the Newark Department of Economic and Housing Development, Carmelo Garcia, was sentenced to prison for his involvement in a corrupt scheme. The scheme involved obtaining bribes and kickbacks from two Newark business owners. This federal prosecution underscores the Department of Justice's ongoing commitment to combating public corruption.
The DEA has issued a proposed rule (Docket No. DEA-1664) that would revoke the exempted status of certain nonnarcotic butalbital-containing prescription products whose National Drug Codes (NDCs) are no longer active — either because the products are unavailable or the applicant company no longer exists. If finalized, these products would be removed from DEA's Table of Exempted Prescription Products and would no longer qualify for exemption under the Controlled Substances Act. Critically, this action does not affect butalbital products with currently active NDC numbers.
The DEA has withdrawn its August 2024 notice of hearing on the proposed rule to move marijuana from Schedule I to Schedule III of the Controlled Substances Act, terminating all related hearing proceedings. Acting under Executive Order 14370, signed by President Trump on December 18, 2025, DEA is initiating entirely new hearing proceedings to complete the rescheduling process more expeditiously. A new notice of hearing was published simultaneously in the same Federal Register issue on April 28, 2026.
The DEA has issued a notice of proposed rulemaking to restructure its regulations governing manufacturing and procurement quotas for Schedule I and II controlled substances, as well as three List I chemicals. The proposed changes aim to improve supply chain visibility, clarify domestic versus export quota categories, and ensure adequate supply to meet medical, scientific, and lawful export needs. Public comments are accepted through July 20, 2026.
The Drug Enforcement Administration has issued a notice of proposed rulemaking to place diphenidine (1-(1,2-diphenylethyl)piperidine), including its salts and isomers, in Schedule I of the Controlled Substances Act. This action is partly driven by U.S. treaty obligations under the 1971 Convention on Psychotropic Substances. If finalized, the rule would impose the full set of Schedule I regulatory controls, civil penalties, and criminal sanctions on anyone who manufactures, distributes, imports, exports, researches, or possesses diphenidine.
FDA has issued a final order classifying the endoscopic suturing device for altering gastric anatomy for weight loss into Class II (special controls) under 21 CFR Part 876, effective May 28, 2026. This De Novo classification — originally applicable as of July 12, 2022 — was initiated by Apollo Endosurgery, Inc. for its APOLLO ESG and APOLLO REVISE systems. The reclassification reduces regulatory burden and allows future substantially equivalent devices to reach market via the less demanding 510(k) premarket notification pathway rather than full Premarket Approval (PMA).
The FDA has proposed removing semaglutide, tirzepatide, and liraglutide from the 503B bulks list, which would effectively prohibit outsourcing facilities from compounding these GLP-1 drugs from bulk substances under most circumstances. The agency determined there is no sufficient clinical need for outsourcing facilities to compound these drugs given the availability of FDA-approved versions. A public comment period is open through June 29, 2026, before a final determination is made.
FDA has classified as a Class I recall — the most serious type — the removal of two specific sterile syringe labels used with Omnicell's i.v.STATION automated IV compounding system. Inconsistent label detection in the system's printers can result in unlabeled or mislabeled syringe preparations after compounding, creating a risk of serious injury or death. Affected facilities are instructed to immediately stop using the recalled labels and revert to previously approved non-sterile labels with yellow backing.
